Treatment of Anxiety in Pregnancy Study (TAPS)

Evaluating an Ultra-Brief Intervention for The Treatment Of COVID-19 Related Anxiety in Pregnant Women

Anxiety Disorders or Depressive Disorders with anxiety, affect about 3/5 pregnancies. It is known that if left untreated, these disorders are associated with poor delivery outcomes, ongoing mental illness, and negative effects on the child. The COVID-19 pandemic has created heightened anxiety in many people especially the most vulnerable. As a result, the investigators have seen that pregnant women report even higher rates of anxiety than in the past. Talk therapy is recommended but is underused in part because it takes a long time to learn and use. The COVID crisis has added another layer of complexity in that in-person treatment is not routinely available. The investigator team has adapted a talk therapy treatment, "Mindful adaptive practice in pregnancy (MAPP)" where women are taught skills to reduce anxiety. This treatment is done virtually over the internet in a synchronous group format. The overall objective of this study is to assess the feasibility, acceptability, and adherence to the clinical trial protocol evaluating MAPP on anxiety symptoms among pregnant women. This synchronous virtual treatment is novel and has the potential to change clinical practice as it will effectively reduce anxiety, takes a short time to learn and women will have access to it regardless of living in rural or remote areas. The results of this study will guide the development of a larger multi-site randomized controlled trial (RCT).

Study Overview

• Status: Recruiting
• Conditions: Pregnancy; Anxiety
• Intervention / Treatment: Other: Treatment as usual (TAU); Other: Mindful Adaptive Practice in Pregnancy Therapy

Detailed Description

Antenatal mental illness is common. About 3/5 of women have antenatal anxiety or depression with anxiety which are both linked to adverse delivery outcomes and negative effects on child development. Often these conditions remain undetected/untreated, perpetuating the cycle of mental illness. A Canadian survey of pregnant women (~2000, April 2020) found >50% endorsed anxiety and > 2/3 elevated anxiety specific to pregnancy during the COVID-19 pandemic. This is on a background of elevated rates of antenatal mental illness. Psychotherapeutic interventions are preferred antenatally but barriers prevent their initiation and adherence (i.e., time duration). With the pandemic and the spike in anxiety, these vulnerable women are at risk to continue being ill and their child at risk for negative delivery/ longer-term outcomes. It is imperative these women receive rapid treatment to reduce acute anxiety to prevent mental health deterioration and the potential adverse effects. The pandemic has also forced clinicians to deliver healthcare in creative ways such as providing psychiatric care virtually despite their not knowing if the therapy can be effectively provided in this way and must be evaluated.

Mindful Adaptive Practice in Pregnancy (MAPP) is a novel ultra-brief psychotherapy developed by the investigator team to reduce anxiety. Prior work (nonclinical samples) suggested high recruitment and retention, significant distress reduction, and enhancement of wellbeing at rates comparable to gold standard therapies of longer duration. The work with clinical samples has shown it to have a large effect size. The investigators have adapted the technique to pregnant women to address the urgent clinical need for a brief, effective targeted intervention. As the investigators were challenged to offer health care services creatively, they adapted MAPP for virtual delivery, in a group format using the Ontario Telemedicine Network for example.

The overall objective of this study is to determine the feasibility, acceptability, and adherence to a clinical trial protocol evaluating the MAPP intervention on anxiety symptoms among pregnant women. The results of this pilot work will guide the development of a larger multi-site randomized controlled trial (RCT) to definitively evaluate the effectiveness of MAPP. As a secondary outcome, the investigators will assess the effect of MAPP in reducing anxious symptoms; this preliminary data on MAPP's effect will inform an effect size for the larger trial power analysis.

Pregnant participants from obstetrics, family practice, midwifery, and reproductive psychiatry clinics, as well as self-referral from social media, will be recruited. Sixty women will be randomized to the control group (standard care) or the intervention group (standard care plus MAPP). Outcomes will be captured electronically right after therapy ends, 3 months post-therapy, and 6 months post-therapy. Results of this work will be used for the larger trial which will have the potential to change clinical practice. Subsequent knowledge translation activities will foster knowledge uptake of the pilot results and once the final RCT is completed, the intervention will be widely disseminated.

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Sophie Grigoriadis, MD, PhD; Phone Number: 416 480 5677; Email: sophie.grigoriadis@sunnybrook.ca
• Study Contact Backup: Name: Morgan Sterling, BAH; Phone Number: 685217 4164806100; Email: morgan.sterling@sunnybrook.ca

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M4N 3M5
      • Recruiting
      • Sunnybrook Health Sciences Center
      • Contact: Sophie Grigoriadis, MD, PhD; Phone Number: 416 480 5677; Email: sophie.grigoriadis@sunnybrook.ca
    • Toronto, Ontario, Canada, M5S 1B2
      • Not yet recruiting
      • Women's College Hospital
      • Contact: Simone Vigod, MD, FRCPC; Phone Number: 4080 416-323-6400; Email: simone.vigod@wchospital.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Pregnant
• >18 years of age
• At 12-30weeks gestation
• Score > 7 on the GAD-7
• Have internet access with camera, microphone, and ability to run the necessary software.
• Fluent in written and spoken English
• Willing to provide the name and contact details of their primary health care provider / other contact who would know person's whereabouts.

Exclusion Criteria:

• Current substance use
• Current psychotic/manic symptoms
• Active suicidal ideation
• Current use of psychotropic medication with dose change within 4 weeks of recruitment
• Currently receiving psychotherapy
• Unwilling to be randomized.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Treatment as usual; All participants allocated to the control group will have access to standard care.	Other: Treatment as usual (TAU); TAU may include self-help methods, physician visit, provision of resources etc.
Experimental: Mindful Adaptive Practice in Pregnancy Therapy; Participants allocated to the intervention group will have access to treatment as usual in addition to synchronous virtual MAPP. MAPP draws upon existing integrative principles of structured psychotherapies (mindfulness-based, cognitive, behavioural and relational psychotherapy)	Other: Treatment as usual (TAU); TAU may include self-help methods, physician visit, provision of resources etc.; Other: Mindful Adaptive Practice in Pregnancy Therapy; MAP teaches: a) recognition of personal maladaptive/ distressing patterns driving anxiety; b) how to relate differently; and c) cultivation of more adaptive ways of dealing with anxiety and learning how to effectively control it rapidly which allows re-engagement with life in more flexible ways.; Other Names: MAPP

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number of participants screened positive for anxiety by the GAD-7 who are eligible for the study.	Among pregnant women who screen positive for anxiety, what is the rate of eligibility? The rate of eligibility will be determined as a raw percentage of the total number eligible over the total pool of participants entering the site.	11 months
The rate of recruitment as assessed by the number of participants recruited	Among eligible pregnant women who screen positive for anxiety, what is the rate of recruitment? The rate of recruitment will be determined as a raw percentage of the number recruited over the number eligible.	11 months
Reasons for non-participation as recorded by participants	Among pregnant women who screen positive for anxiety, what are the reasons for non-participation? Reasons for nonparticipation will also be calculated as a proportion.	11 months
Participant acceptability of treatment as measured by the Treatment Acceptability Scale	What are participants' level of perceived acceptability of the MAPP intervention? The Treatment Acceptability Scale (TAAS) will be used to assess participant acceptability of the intervention. It is a 10 item self report questionnaire where items were developed based on several factors including credibility, expectancy and perceived gaps specifically in the anxiety disorders literature. A 7-point Likert scale is used where higher scores indicate higher acceptability and anticipation to adhere to the intervention. The scale has good psychometric properties and is recommended for evaluating anxiety interventions.	6 weeks
Participant acceptability of treatment as measured by the Acceptability of Internet Delivery (AID)/ Experiences of Therapy Questionnaire	What are participants' level of perceived acceptability of the synchronous virtual group format? For the acceptability of internet delivery (AID), we will use questions that rate the importance of advantages and disadvantages of internet therapy in making a decision regarding using versus rejecting it.	6 weeks
Therapist acceptability of treatment as measured by the Acceptability of Intervention Measures	What are the therapists' perceptions of providing the MAPP intervention in a synchronous group format? For the acceptance of the virtual format, the therapists will complete the Acceptability of Intervention Measure (AIM) a four-item implementation measure that has been referred to as the "leading indicators" of successful implementation with shown psychometric strength and completion time being less than 1 minute.	6 weeks
Therapist acceptability of treatment as measured by questions on the Intervention Appropriateness Measure (IAM)	What are the therapists' perceptions of providing the MAPP intervention in a synchronous group format? For the acceptance of the virtual format, the therapists will complete the Intervention Appropriateness Measure (IAM), a four-item implementation measure that has been referred to as the "leading indicators" of successful implementation with shown psychometric strength and completion time being less than 1 minute.	6 weeks
Therapist acceptability of treatment as measured by the Feasibility of Intervention Measure (FIM) Questionnaire	What are the therapists' perceptions of providing the MAPP intervention in a synchronous group format? For the acceptance of the virtual format, the therapists will complete the Feasibility of Intervention Measure (FIM) a four-item implementation measure that has been referred to as the "leading indicators" of successful implementation with shown psychometric strength and completion time being less than 1 minute.	6 weeks
Participant Adherence to therapy as measured by proportion of participants who attend each session of therapy	What proportion of participants attend each session of therapy Proportion of participants completing each session over all participants for the session	4 weeks
Participant Adherence to therapy as measured by proportion of participants who attend all sessions of therapy	What proportion of participants all therapy session Proportion of participants completing all sessions over all participants	4 weeks
Participant Adherence to therapy as measured by the number completing follow-up questionnaires at 6, 12, and 24 weeks	What number complete all questionnaires at 6,12 and 24 weeks Proportion of participants over all at each time point	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
Participant Adherence to therapy as measured by recorded reasons for dropout	What are the reasons for drop out? Participants who drop out will be asked why and their answers will be recorded	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
Therapist Adherence to Therapy as assessed by therapist adherence checklists	What are the therapists' rate of adherence to the intervention? We will rate the therapists' adherence to the trial protocol by having independent assessors rate adherence by completing a checklist devised for the study intervention based on a previous successfully used framework. Comparisons will be made between therapists and their adherence rates	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Anxiety symptoms as measured by the GAD-7	What is the effect of MAPP on anxiety symptoms compared to the control group at 6 weeks post randomization? The results from this question will be used to generate preliminary data on MAPP's effect on symptoms of anxiety compared to the control condition to inform an effect size for the larger trial power analysis. We will also assess at 12 and 24 weeks The GAD-7 is a 7-item anxiety scale with a min value of 0 and a maximum value of 21, with a higher score indicating higher levels of anxiety.	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinician rated anxiety as assessed by the Hamilton Anxiety Rating Scale (HAM-A)	Hamilton Anxiety Rating Scale (HAM-A) will be used as an objective measure of anxiety (to circumvent contamination of expectation) and completed prior to the other measures. The HAM-A is a 14-item, clinician-rated scale used to assess the severity of anxiety symptoms. Each item is rated on a 5-point likert scale where the total score ranges from 0 to 56. This scale shows good reliability, validity and sensitivity to change. Research staff blind to group will rate the items virtually.	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
Coronavirus anxiety as assessed by the COVID Anxiety Scale (CAS)	The COVID anxiety scale Assesses dysfunctional anxiety associated with the COVID-19 crisis. It has 5 items rated on a 0-4 Likert scale.	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
Participant Depression as assessed by the Edinburgh Postnatal Depression Scale The Edinburgh Postnatal Depression Scale (EPDS)	The Edinburgh Postnatal Depression Scale (EPDS) is an internationally recommended measure for depression symptoms in the perinatal period with well documented psychometric properties for pregnancy. Thirteen items are rated and a cutoff score > 12 will be used as recommended to identify depression.	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
Participant experiences of pregnancy as assessed by The Pregnancy Experiences Scale-Brief Version (PES-B)	The Pregnancy Experiences Scale-Brief Version (PES-B) will be used to measure overall pregnancy experience. It is made up of 10-items with positive and negative stressors specific to pregnancy rated from 0(not at all) to 3(great deal). Each item is rated on one dimension ("hassle or uplift"). We will calculate the intensity of hassles and uplifts (sum of scale scores (1-3)/hassles or uplift frequency. It has good reliability and validity for measuring positive and negative experiences.	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
Participant Healthcare Usage as assessed by the Edinburgh Health Care Utilization (HCU)	The Edinburgh Health Care Utilization (HCU) will be monitored to determine co-intervention or contamination. We will ask participants the number of visits they had with their psychiatrist, family physician for mental health reasons, and start of any treatments during the study period including medication. It has been used successfully in our previous studies with perinatal samples.	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
Participant Coping as assessed by the The Warwick Edinburgh Mental Well-being Scale (WMWS)	The Warwick Edinburgh Mental Well-being Scale (WMWS) will be used to measure coping skills. It consists of 14 positively worded items on scale of 0 to 5. Total scores range from 14 to 70 and it is psychometrically robust and used in pregnant women.	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
What is the effect of MAPP on pregnancy specific stressors	What is the effect of MAPP on pregnancy specific stressors The Pregnancy Related Anxiety Questionnaire R2 (PRAQ-R2) will capture pregnancy specific stressors. The 11 items of the PRAQ-R2 have strong evidence as pregnancy stressors.	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
What is the effect of MAPP on life stressors The Life Stress Inventory (LSI; Holmes & Rahe) general life stressors. The inventory is a well-known tool of 43 life events measuring stress load.	What is the effect of MAPP on life stressors	After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
Adverse effects	We will capture potential adverse effects by using a form made for the trial (Adverse effects form).	6 weeks
Demographics	Demographic information will be collected using a Socio-demographic questionnaire	Baseline
Diagnoses	In order to better describe the sample, especially to be able to classify according to diagnosis, major psychiatric diagnoses will be captured with the Psychiatric Diagnostic Screening Questionnaire (PDSQ). It was developed to be a diagnostic aid in clinical practice and with current psychiatric nomenclature. It is self-report and assesses the most common major psychiatric diagnoses seen in outpatient mental health settings. It has good reliability and validity. While half of participants will randomly receive the PDSQ, the other half will be randomized to receive the Mini International Neuropsychiatric Interview (MINI) anxiety and depression modules. The purpose of using both questionnaires is to validate the PDSQ as an equivalent measurement to the MINI diagnostic inventory in our patient population and will use only the PDSQ for our future large	Baseline
Therapists' activities log-intervention activities	Therapists' activities (session completed / date, telephone discussions if any, missed sessions etc.) will be documented.	4 weeks

Collaborators and Investigators

• Sponsor: Sunnybrook Health Sciences Centre
• Collaborators: Women's College Hospital; Sunnybrook Research Institute
• Investigators: Principal Investigator: Sophie Grigoriadis, MD, PhD, Sunnybrook Health Sciences Center; Principal Investigator: Steven Selchen, MD, FRCPC, Sunnybrook Health Sciences Center

Study record dates

Study Major Dates

• Study Start (Actual): November 21, 2021
• Primary Completion (Anticipated): April 30, 2022
• Study Completion (Anticipated): September 1, 2022

Study Registration Dates

• First Submitted: July 23, 2021
• First Submitted That Met QC Criteria: September 21, 2021
• First Posted (Actual): October 1, 2021

Study Record Updates

• Last Update Posted (Actual): January 4, 2022
• Last Update Submitted That Met QC Criteria: December 13, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Keywords: Mindfulness; anxiety; pregnancy; virtual; pilot; brief psychotherapy
• Additional Relevant MeSH Terms: Mental Disorders; Anxiety Disorders
• Other Study ID Numbers: TAPS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No